Lantern Pharma
LTRN2.6300.75% ( -0.020 )
Lantern Pharma (LTRN)
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical tria...
- Open
- 2.720
- High
- 2.870
- Low
- 2.570
- Prev. Close
- 2.650
- Volume
- 47.91K
- Turnover
- 129.13K
- Avg Price
- 2.695
- Bid/Ask Ratio
- --
- Amplitude
- 11.32%
- 52wk High
- 5.744
- Volume Ratio
- 0.54
- Turnover Ratio
- 0.56%
Lantern Pharma Analyst Rating
View MoreForecast & Rating
May 18, 2026Price forecast
$20.00660.46%
Forecast & RatingStrong buy
2analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- MorningStar · 1 day ago, 10:38 AM
New to The Street TV Announces Broadcast of Show No. 765 Tonight on Bloomberg Television at 6:30 PM ET Featuring Envoy Medical, Graphene Manufacturing Group, Rhino Bitcoin, and Big Sky Industrial
- StockTitan · Jul 27 at 10:45 PM
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer | LTRN Stock News
- StockTitan · Jul 22 at 11:01 PM
Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers | LTRN Stock News
- MorningStar · Jul 18 at 12:03 PM
New to The Street(R) to Broadcast Show #762 Tonight on Bloomberg Television at 6:30 PM ET, Featuring Envoy Medical (NASDAQ:COCH), AlphaCompute (NASDAQ:ALP), RHINO Bitcoin (OTC PINK:RHNO), and Big Sky Industrial (NASDAQ:BSIN)
- PUBT · Jul 13 at 03:39 PM
Lantern Pharma publishes investor presentation on AI-driven oncology drug development platform, pipeline programs
- StockTitan · Jul 7 at 10:30 PM
Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent “Computational Biologist” That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer | LTRN Stock News
